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Introduction
It has become evident that self-reactive T cells with the
potential to cause autoimmune disease comprise a part of
the normal T-cell repertoire, but their activation is prevented
by suppressor cells [1–3]. Although originally described in
the 1970s [4], significant progress in characterizing sup-
pressor T-cell subsets has been made only recently, where
they have been renamed ‘regulatory’ T cells.
A subset of thymus-derived CD4+ cells that constitutively
expresses CD25, the α-chain of the IL-2 receptor, protect
their host from spontaneous organ-specific autoimmune
diseases. These CD4+ CD25+ cells have been called
‘professional’ suppressor cells and have a contact-depen-
dent mechanism of action, at least in vitro [5]. Other
subsets of CD4+ and CD8+ cells, natural killer T cells, and
cells displaying γδ TCRs also have downregulatory (sup-
pressor) activity. In the periphery, suppressor T cells gen-
erated in response to environmental antigens protect their
hosts from immune-mediated tissue injury by producing
immunosuppressive cytokines.
The mechanisms responsible for the generation of sup-
pressor T cells were poorly understood until recently. Our
group has accumulated evidence that the multifunctional
cytokine transforming growth factor-β (TGF-β) plays an
essential role in the expansion of thymus-derived, profes-
sional, CD4+ CD25+ precursors that circulate in the
blood. TGF-β also plays a key role in the generation of
peripherally induced CD4+ and CD8+ cytokine-producing
suppressor cell subsets.
This article will briefly review the evidence for contact-
mediated and cytokine-producing suppressor cells, espe-
cially in humans, and the role of TGF-β in the generation of
these cells. This knowledge can be used to generate sup-
pressor T cells ex vivo in large numbers, and raises the
possibility that the transfer of these cells back to the donor
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Abstract
Regulatory T cells prevent autoimmunity by suppressing the reactivity of potentially aggressive self-
reactive T cells. Contact-dependent CD4+ CD25+ ‘professional’ suppressor cells and other cytokine-
producing CD4+ and CD8+ T-cell subsets mediate this protective function. Evidence will be reviewed
that T cells primed with transforming growth factor (TGF)-β expand rapidly following restimulation.
Certain CD4+ T cells become contact-dependent suppressor cells and other CD4+ and CD8+ cells
become cytokine-producing regulatory cells. This effect is dependent upon a sufficient amount of IL-2
in the microenvironment to overcome the suppressive effects of TGF-β. The adoptive transfer of these
suppressor cells generated ex vivo can protect mice from developing chronic graft versus host disease
with a lupus-like syndrome and alter the course of established disease. These data suggest that
autologous T cells primed and expanded with TGF-β have the potential to be used as a therapy for
patients with systemic lupus erythematosus and other chronic inflammatory diseases.  This novel
adoptive immunotherapy also has the potential to prevent the rejection of allogeneic transplants.
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can serve as a therapy for autoimmune diseases such as
systemic lupus erythematosus (SLE). This T-cell-based
therapy could also be used to prevent graft rejection.
Thymus-dependent, ‘professional’, contact-
dependent, regulatory T cells
The existence of thymus-derived suppressor cells was sug-
gested by studies in mice where neonatal thymectomy  on
day 3 led to the development of a multiorgan autoimmune
disease [6]. This disease is due to the loss of CD4+
CD25+ suppressor cells that do not appear until the first
week after birth [7,8]. Mature CD4+ CD25+ cells are found
in the CD45RBlow activated/memory fraction mouse T
cells. Because potentially aggressive, self-reactive T cells
are found in the CD45RBhi naive fraction of mouse T cells,
the injection of CD45RBhi cells from nonautoimmune,
normal mice into immunodeficient mice results in general-
ized, multiorgan inflammatory disease. Similar to neonatal
thymectomy, this disease is prevented by supplementing
the injected cells with purified CD4+ CD25+ cells [9,10].
Because these thymus-derived CD4+ CD25+ T cells
appear to be crucial for the prevention of spontaneous
autoimmune diseases, they have been called ‘professional’
suppressor cells [5,8].
In general, the properties of rodent and human CD4+
CD25+ T cells appear to be very similar. In humans, 6–18%
of CD4+ T cells constitutively express CD25 [11–17]. Puri-
fied CD4+ CD25+ cells do not proliferate in response to
cross-linking of their TCRs. They inhibit the activation of
other T cells by a contact-dependent mechanism [5–17]. A
large percentage constitutively express intracellular cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA-4 or
CD152), the IL-2 receptor β-chain (CD122), transferrin
receptors (CD71) and class II MHC markers [17].
Almost all the CD4+ CD25+ are in the ‘activated’ state
(CD45RBlow in the mouse, CD45RA– RO+ in the human).
This suggests they may be continuously stimulated by their
internal environment. Although activation of CD4+ CD25+
cells is antigen specific, once these cells are activated they
not only suppress T cells stimulated by the same antigen,
but they also inhibit T cells stimulated by other antigens;
so-called bystander effects [18]. Although CD4+ CD25+
cells are nonresponsive to cross-linking their TCRs, they do
proliferate when costimulated with IL-2 or anti-CD28.
Cytokine production by CD4+ CD25+ cells is controver-
sial. While some groups claim that these cells do not
produce cytokines [8,17], other groups have found that
they can produce IL-10 [12,13,19], TGF-β [15,19], IL-4
[12] and low amounts of interferon-γ [15]. All groups
agree that these cells do not produce IL-2 and that they
have a contact-dependent mechanism of action. Their
suppressive activities are not abolished by neutralizing
antibodies to IL-10, and all groups agree that suppression
is not abolished by anti-TGF-β, but for one exception [19].
Nakamura  et al. reported that immunosuppression by
CD4+  CD25+ regulatory T cells is mediated by cell
surface-bound TGF-β [19]. Many of these differences can
possibly be explained by the heterogeneity of CD4+
CD25+ T cells. One group separated human CD4+
CD25+ cells into high- and low-intensity fractions by cell
sorting, and they found that the suppressive effects were
only displayed by the high-intensity fraction [17]. This
subset did not produce cytokines.
Cytokine-dependent regulatory T cells
CD8+ and CD4+ T cells that produce immunosuppressive
cytokines have been described. Those that produce pre-
dominantly TGF-β and variable amounts of IL-10 and IL-4
have been called Th3-type cells, and they have been gen-
erated in vivo by immunization through an oral or other
mucosal route [2,20]. This route of antigen administration,
however, does not only result in Th3 cells. Both Th2 cells
and CD4+ CD25+ cells can also be generated by this pro-
cedure [20–22]. The conditions needed for the generation
of Th3 cells are poorly understood.
Other workers have produced regulatory CD4+ cells by
repeatedly stimulating with the antigen in the presence of
IL-10 [23–26], or using immature antigen-presenting cells
that lack potent costimulatory activity [27]. These regula-
tory CD4+ cells have been called Treg 1 (Tr1) cells and
they produce significant quantities of IL-10. They do not
proliferate in response to antigen and do not produce IL-2.
Therefore, they are anergic.
Th3 and Tr1-like cells have been described in humans.
One group has reported the appearance of Th3 cells in
patients with multiple sclerosis following oral administra-
tion of myelin basic protein [28]. Human Tr1 cells sup-
pressed an alloantigen-induced proliferative response
[29]. Th3 or Tr1 cells mediate antigen-specific cellular
hyporesponsiveness in patients with chronic helminth
infections [30].
The fact that some regulatory T cells produce predomi-
nantly TGF-β and others IL-10 is not fortuitous. The com-
bination of TGF-β and IL-10 is more immunosuppressive
than either of the cytokines by themselves [31]. Signifi-
cantly, shortly after antigen activation, T cells downregu-
late their signal transducing type II receptor (TGF-βRII)
and become refractory to the effects of TGF-β [32]. These
cells then become mature effector cells. IL-10 appears as
a feedback regulator later in the response and induces the
re-expression of TGF-βRII. The synergistic inhibitory
effects of TGF-β and IL-10 then terminate the response.
Whether Th3 cells and Tr1 cells come from similar precur-
sors or comprise different subsets of regulatory T cells is
not known. Many variables determine the differentiation243
pathway that a naive T cell will take following activation.
These include the antigen concentration and route of
administration, the cytokine milieu, and the pattern of co-
stimulatory signals. Self-MHC-reactive T cells in humans
can either provide B-cell helper function or suppress anti-
body production, depending on how they are activated. In
each case, regulatory function depends on the cytokines
produced [33]. In determining the T-cell response to
myelin basic protein, another group found that TCR usage
was similar whether the T cells became Th1 encephalito-
genic cells or regulatory Th3 cells [34]. These studies
suggest common precursors for T cells that take different
differentiation pathways.
TGF-β β induces CD4+ and CD8+ T cells to
become suppressor cells
While TGF-β has well-known inhibitory effects on lympho-
cyte cytokine production and functional properties [35],
our laboratory has accumulated data that these effects
can be overcome by IL-2 and can be superceded by co-
stimulatory activities. The net effect is that TGF-β induces
IL-2-activated CD8+ and CD4+ T cells to develop potent
suppressive activities. In parallel, other groups have
observed that TGF-β inhibits the differentiation of T cells
to Th1 or Th2 subsets [36,37].
The initial observation that TGF-β is an IL-2-dependent
differentiation factor for regulatory T cells was made in a
study designed to determine the conditions required for
human CD8+ T cells to become suppressors of antibody
production. Using a model where we could induce T-cell-
dependent antibody production without accessory cells,
we found that CD4+ T cells, by themselves, lacked sup-
pressor-inducing activity. The CD4+ cells produced IL-2
but, notwithstanding previous reports [38,39], this
cytokine could not induce suppressor cells by itself. We
learned that the interaction of IL-2-activated natural killer
cells with CD8+ cells leads to the production of active
TGF-β, and that the presence of this cytokine was critical
for CD8+ cells to suppress antibody production (Figure 1)
[40,41]. Moreover, the suppression was cytokine depen-
dent and was abolished by a neutralizing anti-TGF-β
monoclonal antibody (JD Gray and DA Horwitz, unpub-
lished observation, 2000). Both IL-2 and TGF-β were thus
critical for CD8+ cells to become Th3-like regulatory cells.
We have also induced CD4+ T cells to become Th3 cells.
We used the superantigen, staphylococcal enterotoxin B,
as the T-cell activating agent. Low-dose staphylococcal
enterotoxin B can induce T-cell-dependent antibody pro-
duction without additional accessory cells [42]. Briefly
exposing CD4+ cells to TGF-β downregulated B-cell
helper activity and induced certain CD4+ cells to develop
suppressive activity that was neutralized by anti-TGF-β.
Activating both CD4+ and CD8+ cells in the presence of
TGF-β thus induced them to develop cytokine-dependent
suppressive activity [43]. Other workers have also reported
similar effects of TGF-β on CD8+ T cells [44]. One group
found that IL-4 and TGF-β are involved in the differentiation
of naive CD4+ cells to cytokine-producing Th3-type cells
[45]. Another group reported that in vitro differentiation of
Th3-type cells from Th0 precursors from TCR transgenic
mice is enhanced by culture with TGF-β [20].
We next focused our attention on the induction of naive
(CD45RA+ RO–) CD4+ T cells to become suppressor
cells. Using the alloantigens as the T-cell activating agent,
we found that TGF-β induced naive CD4+ T cells to
develop extremely potent suppressive activity. These
CD4+ cells had the phenotype and functional characteris-
tics of ‘professional’ regulatory T cells. Using the genera-
tion cytotoxic T-cell activity and T-cell proliferation to
assess suppressive activity, we learned that the suppres-
sor cells were CD25+, and that a large percentage
expressed CTLA-4. Their suppressive effects were
contact dependent and were not neutralized by anti-TGF-β
or IL-10. Adding less than 1% of these cells to T cells
strongly inhibited the generation of cytotoxic T-lymphocyte
activity by preventing the activation of CD8+ cells [14].
Other workers have also reported that CD4+ CD25+ cells
have potent suppressive effects on CD8+ cells. Rodent
CD4+ CD25+ regulatory cells cause CD8+ cells to enter
cycle arrest [46].
The precursors of the human CD4+ CD25+ T cells induced
by IL-2 and TGF-β appear to be the small number of CD25+
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Figure 1
The role of transforming growth factor-β (TGF-β) in the differentiation
pathway of CD8+ regulatory T cells. In response to antigen stimulation,
the combination of IL-2 produced by CD4+ cells and the active form of
TGF-β produced by natural killer (NK) cells or macrophages (not
shown) induce CD8+ cells to lose their cytotoxic potential and become
regulatory, TGF-β-producing, Th3-like cells. IL-2 also enhances the
extracellular conversion of TGF-β from the latent to the biologically
active form.244
cells in the naive fraction. Although <1% of these cells
express CD25, depletion of these cells abrogated the gen-
eration of suppressive activity in some experiments [14].
The principal difference between the cytokine-induced
CD4+ CD25+ cells and the murine and human positively
selected CD4+ CD25+ cells that are predominantly found in
the CD45RO+ ‘memory’ fraction is their capacity for expan-
sion. The positively selected cells are anergic while the
CD4+ CD25+ cells generated from naive cells can be
expanded in IL-2 and retain their suppressive activity [14].
Studies on the mechanism of action of TGF-β have
revealed that this cytokine has potent costimulatory effects
on IL-2-activated T cells. These effects include upregula-
tion of CD25, CTLA-4 and CD40 ligand expression on
CD4+ cells [14,47], and increased tumor necrosis factor-α
production by both CD4+ and CD8+ cells [47]. The TGF-β
costimulated human CD4+ T cells are resistant to activa-
tion-induced apoptosis. They took up less annexin and
expanded fivefold greater in primary cultures than control,
alloactivated CD4+ T cells [14] (SG Zheng and DA
Horwitz, unpublished observations, 2001). Some workers
have reported that TGF-β can accelerate activation-
induced cell death of some T cells [48,49], while others
observed that this cytokine protected T cells from apopto-
sis [50,51]. We favor the hypothesis that TGF-β promotes
the death of mature Th1 and Th2 cells while protecting
newly generated regulatory T cells from undergoing apop-
tosis. This view is consistent with a report indicating posi-
tive effects of TGF-β on naive T cells [52].
In summary, using several different stimuli to activate T
cells, we have found that the combination of IL-2 and
TGF-β can induce CD4+ and CD8+ T cells to become
either cytokine-producing Th3-like or contact-dependent
professional suppressor cells. In our studies with CD8+
cells, the cultures were always supplemented with IL-2.
When human CD4+ cells are activated in the presence of
TGF-β by irradiated allogeneic stimulator cells or with
superantigens, however, sufficient IL-2 is produced for the
costimulatory effects of TGF-β and suppressor cell differ-
entiation. By contrast, cultures with mouse lymphocytes
must generally be supplemented with IL-2.
As shown in Figure 2, we propose that TGF-β induces
thymic-derived CD25 precursors in the naive fraction of
CD4+ cells to expand and to become contact-dependent
‘professional’ regulatory T cells. TGF-β also induces CD4+
and CD8+ cells that are CD25– to become Th3-like cells.
Although almost all naive CD4+ cells are CD25–, why the
predominant TGF-β effect on T cells in this fraction is the
generation of ‘professional’ regulatory T cells remains to
be determined. Our finding that both IL-2 and TGF-β are
critical in the generation of regulatory T cells is of particu-
lar importance in patients with SLE since production of
IL-2 and the active form of TGF-β is decreased [53].
In vivo effects of Treg
Cloned Th3 cells protect mice from several autoimmune
diseases that include experimental allergic encephalitis,
diabetes mellitus, colitis, and uveitis [20,29,54–56].
Cytokine-producing CD8+ cells were described initially
[55], but reports of CD4+ cells with this characteristic have
become predominant. Cloned Tr1 cells protect rodents
from an experimental colitis [29]. Small numbers of adop-
tively transferred noncloned CD4+ CD25+ cells protect
lymphopenic mice from developing spontaneous organ-
specific autoimmune diseases and also protect animals
from developing graft-versus-host disease [8–10,57].
We have begun to learn whether regulatory T cells gener-
ated  ex vivo with TGF-β can have protective effects in
vivo. For this purpose, we selected a mouse model of SLE
that has a rapid onset. The transfer of parental T cells to
F1 mice can result in acute or chronic graft-versus-host
disease depending on the precursor frequency of CD8+
parental cells reactive against the allogeneic MHC anti-
gens [58,59]. The transfer of DBA/2 T cells into DBA/2 x
C57BL/6 F1 mice results in a lupus-like syndrome with
high titers of anti-DNA antibodies and an immune complex
glomerulonephritis. While alloactivated DBA/2 T cells
accelerated the disease, alloactivation of splenic T cells or
CD4+ cells in the presence of TGF-β markedly sup-
pressed and even prevented the development of the
lupus-like syndrome. Both anti-DNA antibody production
and proteinuria were significantly suppressed [60]. Recent
studies have revealed that these suppressor T cells can
also alter the course of established disease. A single
transfer of 5 million T cells conditioned with TGF-β
markedly improved survival of these mice (SG Zheng and
DA Horwitz, unpublished observations, 2001).
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Figure 2
The role of transforming growth factor-β (TGF-β) in the differentiation
pathway of CD4+ regulatory T cells. Following T-cell activation where a
sufficient amount of IL-2 is produced to overcome the inhibitory effects
of TGF-β, the costimulatory effects of this cytokine induce the
precursors of CD4+ CD25+ T cells to become contact-dependent
‘professional’ suppressor cells or induces CD4+ CD25– cells to
produce immunosuppressive quantities of TGF-β. IFN, interferon; 
Tr-1, Treg 1 regulatory CD4+ cells.245
Since it has been possible to significantly expand regula-
tory T cells generated with TGF-β, it should be possible to
generate sufficient numbers in humans for clinical trials.
Although this will be carried out initially with mitogens as
the T-cell activating agent, the ultimate goal is to induce
autoantigen-specific regulatory T cells. This should be pos-
sible based on the progress being made in characterizing
the pathogenic peptides that trigger autoimmune diseases.
It may even be possible to induce potentially aggressive
naive self-reactive cells to become protective suppressor
cells by activating them with TGF-β. An adoptive
immunotherapy using the patients own T cells that have
regained a protective function they had lost should lack the
serious toxic effects associated with the agents now in use.
This treatment is especially promising in autoimmune dis-
eases characterized by a relapsing and remitting course
such as SLE, inflammatory bowel disease or certain forms
of multiple sclerosis. The adoptive transfer of regulatory T
cells generated ex vivo also has the potential to prevent
the rejection of allogeneic organ transplants.
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